Ozanimod (Zeposia) for the treatment of relapsing multiple sclerosis without a high level of disease activity
In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether ozanimod (trade name: Zeposia) has any advantages or disadvantages compared to interferon beta-1a for the treatment of active relapsing-remitting multiple sclerosis (RRMS) in people who have not had previous treatment or in people who have already had treatment and whose multiple sclerosis is not highly active.
For this assessment, the manufacturer provided two studies involving a total of 1,480 people. 737 of these participants had treatment with interferon beta-1a, and 753 were given ozanimod. The following results were found after one year: